Immunotherapy is a revolutionary cancer treatment strategy that leverages the body’s immune system to fight cancer. While immune checkpoint inhibitors significantly improve the therapeutic outcomes in many tumors, most cancer patients cannot benefit from these.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.

The Hong Kong University of Science and Technology (HKUST) announced today that  its School of Engineering researchers have developed Mixture of Modality Experts (MOME), a groundbreaking large artificial intelligence (AI) model for non-invasive breast cancer diagnosis. Trained on the China’s largest multiparametric MRI (mpMRI) breast cancer dataset, MOME achieves expert-level accuracy in classifying tumor malignancy, comparable to that of radiologists with five+years of experience. This innovative solution is now undergoing extensive clinical validation across more than ten hospitals and partner institutions, including Shenzhen People’s Hospital, the Guangzhou First Municipal People's Hospital, and Yunnan Cancer Center, to validate its effectiveness and ensure real-world applicability.